3.4.21.B10: neurosin
This is an abbreviated version!
For detailed information about neurosin, go to the full flat file.
Word Map on EC 3.4.21.B10
-
3.4.21.B10
-
kallikreins
-
trypsin-like
-
medicine
-
klk8
-
par1
-
diagnostics
-
immunofluorometric
- 3.4.21.B10
- kallikreins
-
trypsin-like
- medicine
- klk8
- par1
- diagnostics
-
immunofluorometric
Reaction
proteolytic cleavage of polypeptides =
Synonyms
GK, hK6, KAL-B, kallikrein 6, kallikrein-6, kallikrein-related peptidase, kallikrein-related peptidase 6, KLK6, KRP/hK6, myelencephalonspecific protease, neurosin, protease M, S01.236, serine protease 18, serine protease 9, SP59, tissue kallikrein 6, zyme
ECTree
Advanced search results
Application
Application on EC 3.4.21.B10 - neurosin
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
diagnostics
medicine
additional information
-
hK6 is involved in normal myelin turnover/demyelination processes, but it is unlikely to self-activate. Possibly it modulates ionotropic glutamate receptors and activates PAR 2
enzyme KLK6 is significantly associated with other prognostic markers in gastroesophageal junction adenocarcinoma and Barrett esophagus, including depth of invasion, indicating its potential as independent biomarker
diagnostics
human tissue kallikrein 6 as a potential marker of laryngeal cancer based on the relevant secretory/releasing protein database
diagnostics
kallikrein-related peptidases are biomarkers for prognosis, diagnosis and therapeutic intervention of cancer. KLK6 gene expression may have clinical utility as a marker of unfavorable prognosis for intracranial tumors
diagnostics
stromal cell-associated expression of kallikrein-related peptidase 6 indicates poor prognosis of ovarian cancer patients
diagnostics
the enzyme might be used as a potential biomarker and therapeutic target for gastric cancer
diagnostics
KLK6 is present in biological fluids either as free form, or bound to alpha1-antitrypsin, and the bound form performs better than total KLK6 as a biomarker of ovarian carcinoma
diagnostics
prognostic biomarker for head and neck squamous cell carcinoma patients
-
developoment of a monoclonal antibody to conform the high expression level of hK6 in ovarian tumor cells. The development of high-quality monoclonal antibodies will facilitate the evaluation of biomarkers and allow further screening tool development for early detection of avarian cancer
medicine
-
kallikrein 6 and other kallikreins have the potential as useful biomarker for salivary gland neoplasms
medicine
-
active hK6 is present in ovarian cancer ascites fluid, provides a rationale for the development of novel therapeutic strategies
medicine
-
Klk6 expression decreases E-cadherin levels at the membrane in concert with cytoplasmic and nuclear accumulation of beta-catenin. Klk6 transgene expression induces keratinocyte proliferation and migration during cutaneous wound healing
medicine
KLK6 is a biomarker for tumor diagnosis and management and a promising therapeutic target. KLK6 expression induces E-cadherin ectodomain shedding and reduces cell-cell adhesion. KLK6-induced E-cadherin ectodomain shedding requires proteolytic activity of matrix metalloproteinase and/or disintegrin and metalloproteinase
medicine
KLK6 is an unfavorable prognostic biomarker for ovarian cancer. KLK6 is transcriptionally upregulated in ovarian cancer, but probably not through alternative mRNA transcript expression, genomic mutation, or steroid hormone induction. Upregulation correlates with cancer stage
medicine
multiple co-operating mechanisms underlie the inactivation of KLK6 expression in breast cancer and provide ways for its pharmacological modulation with potential therapeutic implications
medicine
-
protease M in oligodendrocytes is closely associated with the expression of the myelin basic protein and the PLP gene. Maintenance of myelination is an important function of protease M in oligodendrocytes. The enzyme may be related to the oligodendroglial response to myelin disorders
medicine
-
tumor-associated overexpression of tissue kallikreins contributes to ovarian cancer progression. Possibily effects observed may be due to the activity of only some of the four kallikreins hK4, hK5, hK6, and hK7 under survey
medicine
the enzyme might be used as a potential biomarker and therapeutic target for gastric cancer
medicine
the enzyme might be useful as target for therapeutic intervention in case of intracranial tumors
medicine
-
Klk6 represents an important target for conditions in which pro-inflammatory responses play a critical role in disease development, including multiple sclerosis
medicine
possibility to exploit KLK6 as a novel therapeutic target for Parkinson disease and other synucleinopathies
medicine
-
protease M in oligodendrocytes is closely associated with the expression of the myelin basic protein and the PLP gene. Maintenance of myelination is an important function of protease M in oligodendrocytes. The enzyme may be related to the oligodendroglial response to myelin disorders
-